Premium
Pulmonary fibrosis: A complication of 1,3‐bis(2‐chloroethyl)‐1‐nitrosourea (BCNU) therapy
Author(s) -
Ryan Beverly R.,
Walters Thomas R.
Publication year - 1981
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19810815)48:4<909::aid-cncr2820480408>3.0.co;2-6
Subject(s) - medicine , pulmonary fibrosis , complication , pulmonary toxicity , carmustine , tachypnea , nitrosourea , surgery , radiation therapy , adjuvant therapy , fibrosis , lung , chemotherapy , etoposide , tachycardia
A pediatric patient is reported who experienced fatal progressive pulmonary fibrosis as a complication of 1,3‐bis(2‐chloroethyl)‐1‐nitrosourea (BCNU) therapy. The patient received a cumulative dosage of 1.29 g (1.72 g/m 2 ) over a two‐year period as adjuvant therapy for a medulloblastoma. Two and one‐half years after cessation of therapy, cough, tachypnea and fatigue were noted. Progressive pulmonary insufficiency developed. Pulmonary pathologic findings included interstitial fibrosis and alveolar dysplasia. Other cases of BCNU pulmonary toxicity are cited from the medical literature.